DE60116080T2 - 4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidin-3,4-diol - Google Patents

4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidin-3,4-diol Download PDF

Info

Publication number
DE60116080T2
DE60116080T2 DE60116080T DE60116080T DE60116080T2 DE 60116080 T2 DE60116080 T2 DE 60116080T2 DE 60116080 T DE60116080 T DE 60116080T DE 60116080 T DE60116080 T DE 60116080T DE 60116080 T2 DE60116080 T2 DE 60116080T2
Authority
DE
Germany
Prior art keywords
benzyl
piperidine
hydroxy
ethyl
phenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60116080T
Other languages
German (de)
English (en)
Other versions
DE60116080D1 (de
Inventor
Alexander Alanine
Bernd Buettelmann
Marie-Paule Heitz Neidhart
Georg Jaeschke
Emmanuel Pinard
Rene Wyler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE60116080D1 publication Critical patent/DE60116080D1/de
Application granted granted Critical
Publication of DE60116080T2 publication Critical patent/DE60116080T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C07D211/50—Aroyl radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60116080T 2000-04-25 2001-04-17 4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidin-3,4-diol Expired - Lifetime DE60116080T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00108769 2000-04-25
EP00108769 2000-04-25
PCT/EP2001/004305 WO2001081309A2 (en) 2000-04-25 2001-04-17 4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidine-3,4-diol

Publications (2)

Publication Number Publication Date
DE60116080D1 DE60116080D1 (de) 2006-01-26
DE60116080T2 true DE60116080T2 (de) 2006-08-24

Family

ID=8168543

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60116080T Expired - Lifetime DE60116080T2 (de) 2000-04-25 2001-04-17 4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidin-3,4-diol

Country Status (18)

Country Link
US (1) US6432985B2 (enExample)
EP (1) EP1278730B1 (enExample)
JP (1) JP3831255B2 (enExample)
KR (1) KR100527527B1 (enExample)
CN (1) CN1178914C (enExample)
AR (1) AR028357A1 (enExample)
AT (1) ATE313527T1 (enExample)
AU (1) AU785153B2 (enExample)
BR (1) BR0110233A (enExample)
CA (1) CA2407345C (enExample)
DE (1) DE60116080T2 (enExample)
DK (1) DK1278730T3 (enExample)
ES (1) ES2254422T3 (enExample)
MX (1) MXPA02010573A (enExample)
PE (1) PE20011229A1 (enExample)
UY (1) UY26681A1 (enExample)
WO (1) WO2001081309A2 (enExample)
ZA (1) ZA200208134B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7640062B2 (en) 2000-05-08 2009-12-29 Brainsgate Ltd. Methods and systems for management of alzheimer's disease
US7636597B2 (en) 2002-11-14 2009-12-22 Brainsgate, Ltd. Surgical tools and techniques for stimulation
US7684859B2 (en) 2002-04-25 2010-03-23 Brainsgate Ltd. Stimulation of the OTIC ganglion for treating medical conditions
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
US8010189B2 (en) * 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
EP1976495A2 (en) * 2006-01-06 2008-10-08 Aarhus Universitet Compounds acting on the serotonin transporter
CA2688784A1 (en) * 2007-05-21 2008-11-27 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents
US8008253B2 (en) 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
US7860569B2 (en) 2007-10-18 2010-12-28 Brainsgate, Ltd. Long-term SPG stimulation therapy for prevention of vascular dementia
KR20100135847A (ko) * 2008-03-27 2010-12-27 에보텍 뉴로사이언시즈 게엠베하 Ｎｍｄａ ｎｒ２ｂ―서브타입 선택적 길항제를 사용한 질병 치료 방법
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
WO2010019550A2 (en) * 2008-08-12 2010-02-18 Shiraz Pharmaceuticals, Inc. Method of identifying disease risk factors
PH12013501450A1 (en) 2011-01-10 2013-08-28 Takeda Pharmaceuticals Co Methods and drug products for treating alzheimer`s diseases
US8703763B2 (en) * 2011-03-02 2014-04-22 Hoffmann-La Roche Inc. Bridged piperidine derivatives
US9675796B2 (en) 2013-11-10 2017-06-13 Brainsgate Ltd. Implant and delivery system for neural stimulator
US10752588B2 (en) 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands
EP3233077A4 (en) 2014-12-19 2018-08-08 The Broad Institute Inc. Dopamine d2 receptor ligands
US10271907B2 (en) 2015-05-13 2019-04-30 Brainsgate Ltd. Implant and delivery system for neural stimulator
JP7132218B2 (ja) * 2016-11-08 2022-09-06 エフ．ホフマン－ラ ロシュ アーゲー フェノキシトリアゾール

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
ZA9610745B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
TW498067B (en) 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives

Also Published As

Publication number Publication date
KR100527527B1 (ko) 2005-11-09
DK1278730T3 (da) 2006-05-01
WO2001081309A3 (en) 2002-01-17
DE60116080D1 (de) 2006-01-26
UY26681A1 (es) 2001-10-25
ES2254422T3 (es) 2006-06-16
US20010047014A1 (en) 2001-11-29
CA2407345A1 (en) 2001-11-01
MXPA02010573A (es) 2003-03-10
AU6021301A (en) 2001-11-07
JP2004509837A (ja) 2004-04-02
BR0110233A (pt) 2003-01-21
ZA200208134B (en) 2004-01-22
AU785153B2 (en) 2006-10-05
EP1278730B1 (en) 2005-12-21
PE20011229A1 (es) 2001-12-08
CN1178914C (zh) 2004-12-08
US6432985B2 (en) 2002-08-13
ATE313527T1 (de) 2006-01-15
JP3831255B2 (ja) 2006-10-11
KR20040007216A (ko) 2004-01-24
EP1278730A2 (en) 2003-01-29
CA2407345C (en) 2009-04-07
CN1443166A (zh) 2003-09-17
WO2001081309A2 (en) 2001-11-01
AR028357A1 (es) 2003-05-07

Similar Documents

Publication Publication Date Title
DE60116080T2 (de) 4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidin-3,4-diol
DE69623631T2 (de) 4-aryl-1-phenylalkyl-1,2,3,6-tetrahydropyridine als neurothophe und neuroprotektive wirkstoffe
DE69631370T2 (de) Benzylpiperidine und -piperazine als muscarinantagonisten
DE69631588T2 (de) Benzolpiperidine/pyrrolidine zur verbesserung synaptischer reaktion
DE60211223T2 (de) Piperidinderivate als Kalium-Kanal Blockers
DE60213629T2 (de) Piperidinverbindungen als muscarinantagonisten
DE2363052A1 (de) 3-phenyl-3-aminoalkyl-2,6-dioxo-tetraund -hexahydropyridine, verfahren zu ihrer herstellung und ihre verwendung in pharmazeutischen zubereitungen
DE60025348T2 (de) Ethansulfonyl-piperidin-derivate
DD147537A5 (de) Verfahren zur herstellung von 1,2,4,5-tetra-alkyl-4-aryl-piperidinen
DE602004013427T2 (de) Biaryltetrahydroisochinolin-piperidine als selektive mch-rezeptor-antagonisten zur behandlung von adipositas und verwandten erkrankungen
DE60217934T2 (de) Verfahren zur herstellung von desloratadin
DE69120221T2 (de) Pyrimidin-verbindung und ihr pharmazeutisch annehmbares salz
DE60132782T2 (de) Prodrugs zu nmda-rezeptorliganden
DE4424678A1 (de) Dioxo-thiopyrano-pyridin-carbonsäure-derivate
DE69827614T2 (de) Chinoxalindionen
DE69424816T2 (de) N-Benzylpiperazinverbindungen, Verfahren zu ihrer Herstellung und sie enthaltende Zusammensetzungen
DE2802306A1 (de) Azacycloalkane, azacycloalkene und ihre derivate
DE69738349T2 (de) Anthranilsäurediamid-derivate, ihre herstellung und pharmazeutische verwendung als antigastrinmittel
DE60204046T2 (de) N-heterocyclylhydrazide als neurotrophe mittel
EP0891322B1 (de) Dimethyl-substituierte cyclohexandienderivate
DE1645901C3 (de) gamma-(4-Alkylp!peridino)-p-fluorbutyrophenone und Verfahren zu ihrer Herstellung
DE69612626T2 (de) Hydrat-kristall und verfahren zu seiner herstellung
DE19703985A1 (de) Tetrahydroisochinolinderivate
DE60105221T2 (de) Verfahren zur Herstellung vom Mesylat Salz des Trihydrats des 1-(4-Hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanols und Zwischenprodukte für dieses Verfahren
DE69203809T2 (de) Piperidinderivat und dieses enthaltende pharmazeutische Zubereitung.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition